The HANDI Resources Center Team is pleased to announce new 2024 scholarship opportunities available for the bleeding disorders community!Kevin Child Scholarship (KCS)The KCS awards $1,000 to eligible individuals living in the U.S.…
Keeping Your Informed In a significant development within the gene editing arena, Intellia Therapeutics has announced its decision to opt out of a hemophilia B program, relinquishing control of CRISPR/Cas9-based gene editing…
Speakers: Samantha Carlson, LMSW, and Halli Benasutti, Ph.D.Join Samantha Carlson, LMSW Director of Research & Halli Benasutti, Ph.D., Director of Research Grants, as they outline the 2024 funding opportunities…
A new paper published in The Lancet Haematology journal includes data from the HOPE-B clinical trial program that is investigating the hemophilia B gene therapy etranacogene dezaparvovec – the product’s commercial name is Hemgenix® (CSL Behring).…
Celebrate World Hemophilia Day: Raise Awareness and Empower Lives Join us on April 17th as we come together to celebrate World Hemophilia Day! This global event is dedicated to raising awareness about hemophilia and other bleeding…
U.S. Hemophilia Treatment Centers (HTCs) are once again participating in the National HTC Patient Satisfaction Survey (PSS). It is launched every three years to help glean valuable feedback from HTC patients and caregivers, with the overarching goal…
Financing a higher education poses considerable challenges, especially as yearly tuition and other school-related costs continue to rise. For many individuals and families considering a higher education, awareness of any opportunities to defray…
For Immediate Release CONTACT: Kyla Clark National Bleeding Disorders Foundation 347-920-0047kclark@bleeding.org NBDF Announces Transition from Hemophilia.org to Bleeding.org New…